A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: bevacizumab|DRUG: docetaxel|DRUG: doxorubicin|DRUG: cyclophosphamide|DRUG: pegfilgrastim
Sponsor: NSABP Foundation Inc
Collaborators: Genentech, Inc.|US Oncology Research